CLINICAL AND NEUROLOGICAL ASPECTS OF MULTIPLE SCLEROSIS DURING INFECTION WITH COVID-19 IN UZBEKISTAN.

Yakubova M.M; Khalimova H.M; Parpieva Yu.R

doi:10.17605/cajmns.v2i3.197

Yakubova M.M Doctor of Medical Sciences, Professor of the Department of Nervous Diseases of the Tashkent Medical Academy.
Khalimova H.M Doctor of Medical Sciences, Professor of the Department of Nervous Diseases of the Tashkent Medical Academy.
Parpieva Yu.R

DOI: https://doi.org/10.17605/cajmns.v2i3.197

Keywords: multiple sclerosis, Coronavirus Disease, pandemic, remission

Abstract

The COVID-19 problem is relevant all over the world, in particular in Uzbekistan. At the end of 2019, WHO declared a new disease caused by SARS-CoV-2 - COVID-19 (Coronavirus Disease), in the status of a "pandemic" [9]. Coronavirus primarily affects the respiratory tract, being a significant pathogenetic agent. However, damage to the respiratory system is not the only and exclusive COVID-19 syndrome. Many studies have described the involvement of the nervous system in this disease. The coronavirus pandemic contributed to the assessment of the comorbidity of neurological pathologies, the degree of course and complication of existing diseases, including multiple sclerosis. The outcome in this case can become sharply threatening health which becomes social in nature as a result.

References

Boyko A.N., Lasch N.Yu., Spirin N.N., Sivertseva S.A., Martynov M.Yu. "Management of patients with multiple sclerosis in the context of the COVID-19 pandemic" 04/19/2020);

Boyko AN 1,2, Sivertseva SA 3, Spirin NN 4 Neurology, neuropsychiatry, psychosomatics. 2020 page 45);

Baig AM, Khaleeq A, Ali U, Syeda H. Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host-Virus Interaction, and Proposed Neurotropic Mechanisms. ACS Chem Neurosci. 2020 Apr 1; 11 (7): 995-998. doi: 10.1021 / acschemneuro.0c00122. Epub 2020 Mar 13.;

Desforges M., Le Coupanec A., Stodola J.K. et al. Human coronaviruses: viral and cellular factors involved in neuroinvasiveness and neuropathogenesis. Virus Res 2014; 194: 145-158. DOI: 10.1016 / j.virusres.2014.09.011. PMID: 25281913 .;

Gu J., Gong E., Zhang B. et al. Multiple organ infection and the pathogenesis of SARS. J Exp Med 2005; 202: 415-424. DOI: 10.1084 / jem.20050828. PMID: 16043521 20. Dubé M9;

Jacob S, Muppidi S, Guidon F, et al. Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic. J Neurol Sci. 2020 May 15; 412: 116803. doi: 10.1016 / j.jns.2020.116803. Epub 2020 Mar 25 .;

Mao L, Wang M, Chen S, et al. Neurological Manifestations of Hospitalized Patients with COVID-19 in Wuhan, China: A Retrospective Case Series Study. MedRxiv preprint. doi: 10.1101/2020.02.22.20026500;

Matías-Guiu J., Gomez-Pinedo U., Montero-Escribano P. et al. Should we expect neurological symptoms in the SARS-CoV-2 epidemic? Neurologia 2020; 35: 170–175. DOI: 10.1016/j.nrleng.2020.03.002. PMID: 32299636;

Miwa T., Ikeda K., Ishibashi T. et al. Clinical practice guidelines for the management of olfactory dysfunction — secondary publication. Auris Nasus Larynx 2019; 46: 653–662. DOI: 10.1016/j.anl.2019.04.002. PMID: 31076272;

Poyiadji N, Shahin G, Noujaim D, et al. COVID-19-ssociated Acute Hemorrhagic Necrotizing Encephalopathy: CT and MRI Features. Radiology 2020 March 31:201187. https://doi.org/10.1148/radiol.2020201187;

https://cdn.ymaws.com/www.theabn.org/resource/collection/6750BAE6- 4CBC4DDBA684.